Revance Therapeutics, Inc.

Good day, everyone. Welcome to RELAND's Therapeutic Second Quarter 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following the management's prepared remarks, we will hold a Q&A session. To ensure that we will have ample time to address everyone's questions during Q&A, we would like to ask for a limit of one question and one follow-up question per person. To ask a question during that time, please press star followed by one on your touchtone phone. If anyone has difficulty hearing the conference call, please press star zero for operator assistance. As a reminder, this call is being recorded today, August 5, 2021. I would now like to turn the conference over to Jessica Serra, Head of Investor Relations at ESG for Revents. Please go ahead.

Thank you, Anna. Joining us on the call today is President and Chief Executive Officer Mark Foley, Chief Financial Officer Toby Schulte, Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi, Chief Commercial Officer, Aesthetics and Therapeutics, Justice Suits, and President of Innovation and Technology, Operating Banking. During the conference call, management will make forward-looking statements. essential benefits of our drug product candidates and technologies, the launch of the next generation FinTech platform, the timing of any potential approval of that for injection, 2021 guidance, expected cash runway of the . These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the time used could differ materially from the anticipated as a result of these risks. Also in today's call, we will present both GAAP and non-GAAP financial measures, a reconciliation of non-GAAP and GAAP measures included in our earnings rules. For that, I will turn the call over to Mark Holder. Mark?

Thank you, Jessica. Good afternoon, everyone, and thank you for joining our second quarter 2021 financial results conference call. We're very pleased to report strong second quarter results, highlighted by $17 million in RHA revenue, over 2,000 aesthetic accounts shared across products and services, and over $500 million in FinTech processing volume run rate. Our focus on execution, supported by a healthy aesthetics market, led to our third consecutive quarter of revenue growth since becoming a commercial entity and further validated our commercial launch strategy. These results would not have been possible without the entire revamped organization working together as a team. I continue to be impressed by the exceptional talent we've been able to attract to the company and by their unwavering commitment and dedication to deliver on our objectives. With the FDA having initiated their pre-approval inspection of our manufacturing facility in June, we continue to anticipate the approval of our lead product, Dactymoduline Intoxinate for Injection, for the treatment of glabellar lines this year. In the meantime, the revamp team is actively building inventory and solidifying our commercial launch plans for our innovative neuromodulator. We look forward to introducing the first true innovation in their neuromodulator category in over 30 years, and once approved, Daxibotulinum Toxin A for injection will not only anchor our aesthetics portfolio, but also lay the foundation for our therapeutics franchise. We expect the second half of the year to be very busy and exciting, particularly as we anticipate several catalysts in our therapeutics pipeline, which I will cover later in this call. With that, let me turn the call over to Dustin.